IQWiGInstitut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (German: Institute for Quality and Efficiency in Health Care)
IQWiGInstitute for Quality and Efficiency in Health Care (Germany)
Copyright 1988-2018, All rights reserved.
References in periodicals archive ?
The IQWiG researchers investigated a range of therapeutic situations.
According to a senior minister in the German Health Ministry, "most patients and doctors usually accept IQWiG's recommendations." American health care policy expert Uwe Reinhardt, who saw the IQWiG in action and marveled at its effectiveness, told critics of the Independent Payment Advisory Board: "Go to Germany, study [the IQWiG], and you will find that this really works.
Despite the approval of pirfenidone in the European Union (EU), IQWiG concluded that no additional benefit could be found for the drug.
Overall, IQWiG and its external experts included 8 randomised controlled trials lasting 6 to 12 months in the assessment.
The German Institut fur Qualitat und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) and the French HAS are equally at arm's length from insurers and government; however, their assessments have no direct impact on patient access or entitlement.
The government continued its efforts to reduce the influence of the collective bodies on such decisions in the 2004 Health Reform, which established an Institute for Quality and Efficiency in Health Care (IQWiG) with wide-ranging powers to evaluate the benefit and efficiency of diagnosis and treatment methods.
The Institute for Quality and Efficiency in the Health Care Sector (IQWiG), founded in 2004, is supposed to provide research and advice.
In Germany the NICE counterpart (Iqwig) ruled in 2005 that Lipitor (atorvastatin) offered insignificant clinical benefits compared with its off-patent rivals.
In its analysis, IQWiG concluded that, based on results from the TAILORx study, the Oncotype DX Breast Recurrence Score test can support patients with primary node-negative, hormone-receptor positive, HER2-negative breast cancer in the decision for or against chemotherapy.